Generated by AI
Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms. These technologies support the discovery, development, and manufacture of biologic drug candidates intended for oncology and other immune-related diseases. Sutro Biopharma’s work centers on creating precisely engineered therapies for solid tumors and hematologic cancers, while also supporting collaborative research and development efforts with pharmaceutical partners. Headquartered in South San Francisco, California, Sutro Biopharma plays a specialized role in the biopharmaceutical market by combining protein engineering, drug conjugation, and therapeutic development within a single platform-driven approach.
Website111 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about STRO.
Summary of Oct 13's posts. Generated by AI.
No summary yet.
Summary of Mar 17's posts. Generated by AI.
Summary of Apr 2's posts. Generated by AI.
Summary of Feb 10's posts. Generated by AI.
Investors talking about STRO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.